

Who can participate in this study?

You may qualify to participate if you meet the following requirements:

- At least 18 and up to 65 years of age
- Diagnosed with non-segmental vitiligo
- Have prior medical history or use of prior medications or therapies (including prior vitiligo medications or therapies) that are acceptable for the study

What is vitiligo?

Vitiligo is a common, chronic, autoimmune disorder of the skin characterized by depigmented skin lesions, and it is associated with an impaired quality of life. It affects approximately 0.5 to 2% of the population including adults and children.

What happens next?

If you think you may be interested in participating in this study, please let the study doctor know. The study doctor or study staff will give you an informed consent form to review and discuss. An informed consent form is a document that has information about research studies and details about what your participation may look like.

What if I still have questions?

It is normal to have questions. Please contact your doctor, the study doctor, or the study staff to ask any questions and to figure out whether participating is right for you. You may also find useful resources online. Here are some examples that can help you:

- Understand more about clinical research www.hhs.gov/About-Research-Participation
- Learn more about what participating may mean for you by visiting AbbVie's online resource www.ClinicalTrialsAndMe.com

Now recruiting for a Phase 2 vitiligo clinical research study (M19-051)

obbyje



M19-051 Patient Pamphlet v2 4May2021

abbvie

What is a clinical research study?

A clinical research study is medical research with human volunteers to learn more about investigational new drugs. Clinical research studies help us understand safety and effectiveness of the study drug being researched.

Volunteers for clinical research have different reasons for participating, including:

- · Contributing to the advancement of science
- Gaining access to investigational study drug or study procedures

The researchers will closely monitor health and protect privacy of participants.

Study procedures

At study visits, the study staff may perform routine checks to monitor health and safety, administer study treatment, and check vitiligo symptoms (not all procedures are included here).

(Y)

Vital sign check and physical exam

Pregnancy test

(if you are a woman and can have children)

Vitiligo assessments

(includes participant and physician assessments)



Urine test

ECG

(electrocardiogram)



Study drug administration

What are the study treatments?

The investigational study drug is being studied in people with vitiligo. The study drug blocks the action of proteins known as Janus kinases (Jaks). Jaks are involved in the immune response and cell growth including blood cells. The study drug is being tested to see if it is safe and effective for treating adult subjects with non-segmental vitiligo.

In this study, the study drug will be compared to a placebo. A placebo looks like the study drug but does not have any study drug in it. A placebo can help researchers understand if the study drug is effective and safe.

You should ask the study staff any questions you have about the investigational study drug.

What happens if I am assigned placebo?

Study participants are assigned to receive the investigational study drug or placebo at random for the first 24 weeks of the study. Neither you nor the study doctor and staff will know what study treatment you are assigned to receive. However, you have a 75% chance of being assigned to receive the study drug versus placebo. After 24 weeks of study treatment, all study participants will receive the investigational study drug for the next 28 weeks of study treatment.

You should talk to your study doctor about any other medication or treatment you are using while you participate in the study.

What happens if I want to participate?

You may be able to participate after the following:

- Informed Consent: Agreeing to participate in the research study after reviewing the Informed Consent Form with study staff and/ or family and friends
- Screening: Answering questions about your medical history and completing screening assessments such as blood tests, a physical exam, and an ECG

What will my commitment look like?

While you are in the study, you will be seen regularly by the study doctor and study staff to monitor your health and safety.

- **Visit frequency:** During the first month of the study, you will have study visits every 2 weeks and then up to week 52 you will have study visits every 4-8 weeks
- Study length: Up to 60 weeks

Participating in the study is voluntary—you can stop participating at any time for any reason.

